STING & TLR-Targeting Therapies Summit

Memo

This is the definitive drug development forum for research teams to investigate how to modulate the cGAS-STING and Toll-like receptor (7/8/9) pathways both as monotherapies and as adjuvants in combinatorial approaches. This meeting comes at a critical point for the cancer immunotherapy field, as researchers look to increase patient response rates and the efficacy on checkpoint inhibitors in several solid tumor indications. Preclinical and early clinical data for modulators of the STING & TLR plus other innate immune checkpoint inhibitors has been hugely promising. Use this key forum to hone your innate immune activation strategies and deliver safe and effective treatments through systematic and intra-tumoral administration which can stimulate the adaptive immune arm, counteract solid tumor-induced immunosuppression and increase response to checkpoint inhibitors. Innate Immune Checkpoints & Activation Pre-Focus Day In addition to two full conference days to STING/TLR-targeting, there will be a pre-focus day specifically on innate immune checkpoints and the activation of specific cell types including natural killer cells, macrophages and myeloid-derived suppressor cells. An executive speaker faculty will take you through the leading drug candidates aimed at inhibitory and activation receptors on key cellular component of the innate immune system. To learn more, visit www.sting-tlr-targeting-therapies.com Brochure https://go.evvnt.com/739379-0?pid=5569Tickets https://go.evvnt.com/739379-1?pid=5569 Prices:Conference + Pre Focus Day (Pay by Friday, February 26) USD 1798.00,Conference + Pre Focus Day (Pay by Friday, March 19) USD 1948.00,Conference + Pre Focus Day (Pay by Friday, April 16) USD 2148.00,Conference + Pre Focus Day (Pay by Friday, May 7) USD 2348.00,Conference + Pre Focus Day (Standard Rate) USD 2498.00,Conference Only (Pay by Friday, February 26) USD 1499.00,Conference Only (Pay by Friday, March 19) USD 1599.00,Conference Only (Pay by Friday, April 16) USD 1749.00,Conference Only (Pay by Friday, May 7) USD 1899.00,Conference Only (Standard Rate) USD 2498.00, Speakers: Laura Glickman, Vice President, Research & Co- Founder, Actym Therapeutics, Andrew Miller, Vice President of Immunology and Operations, Apros Therapeutics, Sebastian Carotta, Scientific Director, Cancer Cell Signalling, Boehringer Ingelheim, Edith Perez, Chief Medical Officer, Bolt Biotherapeutics, Sean Lawler, Associate Professor of Neurosurger, Brigham and Women’s Hospital Harvard Medical School, Art Krieg, Founder, Chief Scientific Officer, Checkmate Pharmaceuticals, Kyriakos Economides, Director of Pharmacology, Codiak Biosciences, Michael Newman, President & Chief Executive Officer, Decoy Biosystems, Joshi Ramanjulu, Senior Director, Head of Project Leader Group & Senior GSK Fellow, Innate Immunity Research Unit, GSK, Sonia Macia, Director, Medical, Highlight Therapeutics, Sophie Agaugue, Director & Senior Lead - Research Operations & Scientist Project, ImCheck Therapeutics, Roxana Schillaci, Principal Researcher, Institute of Biology and Experimental Medicine (IBYME), CONICET, Adi Diab, Associate Professor, Melanoma Medical Oncology, MD Anderson, Jeremy Duvall, Associate Director Chemistry, Mersana Therapeutics, Naniye Malli Cetinbas, Senior Scientist, Mersana Therapeutics, Daniel Getts, Co-Founder & Chief Executive Officer, Myeloid Therapeutics, Nicholas Huntington, Co-Founder & Chief Scientific Officer, oNKo-innate, James Appleman, Senior Vice President R&D & Chief Scientific Officer, Primmune Therapeutics, Krysztof Brzozka, Chief Scientific Officer & Executive Vice President, Ryvu Therapeutics, Robert Andtbacka, Chief Medical Officer, Seven and Eight Biopharmaceuticals, Woody Sherman, Chief Scientific Officer, Silicon Therapeutics, Christopher Winter, Chief of R&D, Silicon Therapeutics, Martin Roelsgaard Jakobsen, Chief Scientific Officer, STipe Therapeutics, Hong Wan, Chief Executive Officer, Tallac Therapeutics, Bettina Werle, Chief Scientific Officer, Tollys, Bob Uger, Chief Scientific Officer, Trillium Therapeutics, Kate Fitzgerald, Professor, Director, Program in Innate Immunity, UMass, Diwakar Davar, Assistant Professor of Medicine, UPMC, Tatiana Novobrantseva, Co-Founder & Chief Scientific Officer, Verseau Therapeutics, Johannes Grosse, Senior Director, Drug Discovery, Vir Biotechnologies, Jim Eyles, Associate Director, AstraZeneca, Kimmy Kin-Mei Leung, Project Leader, F-star Therapeutics, Arndt Schottelius, Chief Scientific Officer, Affimed Time: On Tuesday May 25, 2021 at 8:00 am (ends Thursday May 27, 2021 at 6:00 pm)